DexCom, Inc. (DXCM) - Product Pipeline Analysis, 2013 Update, New Report Launched

DexCom, Inc. (DexCom) is a medical device company. The company operates in the design, development and selling of continuous glucose monitoring systems for ambulatory. It gained support for its third generation system, the SEVEN PLUS, from the US Food and Drug Administration (FDA). DexCom’s products are for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The company’s membrane technology has several polymer layers organized for selective permit for the appropriate mix of oxygen and glucose to move through the membrane and react with a glucose specific enzyme. Its ambulatory glucose examining systems use radiofrequency telemetry for wireless broadcast information from the transmitter in a pod atop the sensor till receiver. DexCom small handheld receiver is carried by the patient and wirelessly receives continuous glucose values from the sensor. DexCom is headquartered in San Diego, California, the US.

This report is a source for data, analysis and actionable intelligence on the DexCom, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

• Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
• Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
• Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
• Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
• Data on relevant clinical trials and product patent details, wherever applicable.
• Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
• Design and develop your product development, marketing and sales strategies.
• Exploit M&A opportunities by identifying market players with the most innovative pipeline.
• Develop market-entry and market expansion strategies.
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
• Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

Inquiry for more information visit:  DexCom,Inc. (DXCM) - Product Pipeline Analysis, 2013 Update